Regulations and other acts

Gouvernement du Québec

O.C. 142-2003, 12 February 2003

Podiatry Act
(R.S.Q., c. P-12)

Podiatrist
— Medications
— Amendments

Regulation to amend the Regulation respecting the medications that a podiatrist may use in the practice of his profession or administer or prescribe to his patients

WHEREAS, under section 12 of the Podiatry Act (R.S.Q., c. P-12), the Office des professions du Québec shall prepare periodically, by regulation, after consultation with the Conseil consultatif de pharmacologie, the Ordre des podiatres du Québec, the Ordre des médecins du Québec and the Ordre des pharmaciens du Québec, a list of the medications which a podiatrist may use in the practice of his profession or which he may administer or prescribe to his patients, and determine, where required, the conditions subject to which a podiatrist may administer and prescribe such medications;

WHEREAS, under that section, the Office des professions du Québec made the Regulation respecting the medications that a podiatrist may use in the practice of his profession or administer or prescribe to his patients, approved by Order in Council 1057-91 dated 24 July 1991;

WHEREAS, under that section, the Office made the Regulation to amend the Regulation respecting the medications that a podiatrist may use in the practice of his profession or administer or prescribe to his patients, at its sitting of 22 November 2001;

WHEREAS, in accordance with sections 10 and 11 of the Regulations Act (R.S.Q., c. R-18.1), a draft of the Regulation attached to this Order in Council was published in the *Gazette officielle du Québec* of 23 January 2002 with a notice that it could be made by the Government upon the expiry of a 45-day period following that publication;

WHEREAS, in accordance with section 13 of the Professional Code (R.S.Q., c. C-26), the Office des professions du Québec is submitting this Regulation to the Government for approval;

WHEREAS it is expedient to approve the Regulation without amendment;

IT IS ORDERED, therefore, upon the recommendation of the Minister responsible for the administration of legislation respecting the professions:

THAT the Regulation to amend the Regulation respecting the medications that a podiatrist may use in the practice of his profession or administer or prescribe to his patients, attached to this Order in Council, be approved.

JEAN ST-GELAIS,
Clerk of the Conseil exécutif

Regulation to amend the Regulation respecting the medications that a podiatrist may use in the practice of his profession or administer or prescribe to his patients*

Podiatry Act
(R.S.Q., c. P-12, s. 12)

1. Section 1 of the Regulation respecting the medications that a podiatrist may use in the practice of his profession or administer or prescribe to his patients is amended

(1) by substituting the words “listed in Schedule I or in Schedule II, subject to the conditions prescribed in this Regulation” for the words “described in Schedule I”;

(2) by adding the following paragraphs at the end:

* The Regulation respecting the medications that a podiatrist may use in the practice of his profession or administer or prescribe to his patients, approved by Order in Council 1057-91 dated 24 July 1991 (1991, *G.O.* 2, 3231), has not been amended.

"A podiatrist who administers or prescribes to patients the medications listed in Schedule II that are not medications listed in Schedule I must hold a certificate issued by the Ordre des podiatres du Québec acknowledging that the podiatrist received university training in podiatric medicine in the last five years, comprising a minimum of 1145 hours apportioned as follows:

(1) 540 hours in anatomy-physiology;

(2) 90 hours in biochemistry;

(3) 105 hours in microbiology;

(4) 275 hours in general pathologies;

(5) 90 hours in basic pharmacology; and

(6) 45 hours in clinical pharmacology.

A podiatrist whose training referred to in subparagraphs 1 to 6 of the second paragraph was received more than five years previously must successfully complete the continuing education activities determined by the Ordre des podiatres du Québec pursuant to paragraph *o* of section 94 of the Professional Code (R.S.Q., c. C-26) and hold a certificate issued by the Order acknowledging that the activities were successfully completed, before the medications listed in Schedule II that are not medications listed in Schedule I may be administered to patients.".

2. Section 2 is revoked.

3. The following Schedules are substituted for Schedule I:

"SCHEDULE I

NOTE: Medications without specification are intended for topical application.

Substances	Specification
Acetaminophen	Pharmaceutical forms intended for oral and rectal administration
Acetic, glacial acid	
Acetylsalicylic, acid	Pharmaceutical forms intended for oral administration
Aluminium and its salts	
Almond, sweet oil	
Amino acids	
Amcinonide	Quantity limited for 30 days
Anthralin (dithranol)	
Silver nitrate	
Silver sulfadiazine	
Colloidal oatmeal	
Bacitracin and its salts	
Beclomethasone and its salts	
Benzalkonium	
Benzocaine	
Betamethasone benzoate	
Betamethasone dipropionate	Quantity limited for 30 days
Betamethasone valerate	
Bupivacaine and its salts	Pharmaceutical forms intended for administration by injection for local use only
Calcipotriol	
Calcium acetate	
Camphor	
Cantharin	
Capsaicin	
Cetrimide	
Cetirizine hydrochloride	Pharmaceutical form intended for oral administration
Chlorhexidine and its salts	
Chlorphenesin	
Chlorprocaine hydrochloride	Pharmaceutical form intended for administration by injection for local use only
Ciclopirox olamine	
Cinchocaine	
Clioquinol (iodochlorhydroxyquin)	
Clobetasol proprionate	Quantity limited for 30 days
Clobetasone butyrate	
Clotrimazole	
Collagenase	
Dakin's solution	
Desonide	
Desoximetasone	Quantity limited for 30 days

Substances	Specification
Deoxyribonuclease	
Dichloracetic acid	
Diflucortolone valerate	Quantity limited for 30 days
Diphenhydramine	Pharmaceutical forms intended for oral and topical administration
Econazole nitrate	
Epinephrine (adrenaline)	Pharmaceutical forms for the emergency treatment of anaphylactic reactions in the form of self-injector or ampoule
	Pharmaceutical form associated with local anaesthetics
Erythromycin	
Ethyl chloride	
Fibrinolysin	
Flumetasone pivalate	
Fluocinolone acetonide	Quantity limited for 30 days
Fluocinode	Quantity limited for 30 days
Formalin	
Framycetin sulfate	
Fusidic acid	
Gentamicin sulfate	
Gentian, violet	
Mineral and vegetal tar	
Gramicidin	
Halcinodide	Quantity limited for 30 days
Hexachlorophene	
Mineral oil	
Hydrocortisone and its salts	
Hydroxyzine hydrochloride	Pharmaceutical form intended for oral administration
Povidone iodine	
Iodine tincture	
Isopropyl myristate	
Ketoconazole	
Lactic acid	
Lanolin	
Lidocaine and its salts	Pharmaceutical forms intended for topical application and administration by injection for local use only
Loratadine	Pharmaceutical form intended for oral administration
Mafenide and its salts	
Menthol	
Mepivacaine	Pharmaceutical form intended for administration by injection for local use only
Methylpolysiloxanes	
Methylprednisolone acetate	
Miconazole nitrate	
Mometasone furorate	
Mupirocin	
Neomycin sulfate	
Nystatin	
Oxiconazole	
Phenol	
Podophyllin	
Polymyxin B sulfate	
Pramoxine	
Prilocaine	Pharmaceutical forms intended for topical application and administration by injection for local use only
Procaine	Pharmaceutical form intended for administration by injection for local use only
Resorcinol and its salts	
Diethylamine salicylate	
Magnesium salicylate	
Methyl salicylate	
Triethanolamine salicylate	
Salicylic acid	
Synthetic sebum	
Silicone	
Sodium thiosulfate	
Sulphur, colloidal, precipitate or sublimate	
Tazarotene	
Terbinafine	
Tetracaine and its salts	Pharmaceutical forms intended for topical application and administration by injection for local use only

Substances	Specification
Tioconazole	
Tolnaftate	
Triamcinolone acetonide	Quantity limited for 30 days
Trichloroacetic acid	
Urea	Pharmaceutical form intended for topical application, with a concentration of 30% or less
White petroleum jelly	
Zinc oxide	

SCHEDULE II

NOTE: Medications without specification are intended for topical application.

Substances	Specifications
Acetaminophen	Pharmaceutical form intended for oral and rectal administration
Acetaminophen and codeine (in combination)	Pharmaceutical form intended for oral administration containing 30 mg and less of codeine per tablet
Acetic, glacial acid	Quantity limited to 24 tablets/72 hours
Acetylsalicyclic acid	Pharmaceutical form intended for oral administration
Aluminium and its salts	
Almond, sweet oil	
Amcinonide	Quantity limited for 30 days
Amino acids	
Anthralin (dithranol)	
Silver nitrate	
Silver sulfadiazine	
Colloidal oatmeal	
Bacitracin and its salts	
Beclomethasone and its salts	
Benzalkonium	
Benzocaine	
Betamethasone benzoate	
Betamethasone dipropionate	Pharmaceutical forms intended for topical application and administration per intradermal or intramuscular injection
	Quantity limited for 30 days
Betamethasone valerate	
Bleomycin sulfate	Pharmaceutical form injectable in the plantar lesion without exceeding 0.8 unit up to a maximum of 5 units per treatment
Bupivacaine and its salts	Pharmaceutical form intended for administration by injection for local use only
Calcipotriol	
Calcium acetate	
Camphor	
Cantharin	
Capsaicin	
Celecoxib	Pharmaceutical form intended for oral administration
	Quantity limited for 30 days
Cetirizine hydrochloride	Pharmaceutical form intended for oral administration
Cetrimid	
Chlorhexidine and its salts	
Chlorphenesin	
Chlorprocaine hydrochloride	Pharmaceutical form intended for administration by injection for local use only
Ciclopirox olamine	
Cinchocaine	
Clioquinor (iodochlorhydroxyquin)	
Clobetasol proprionate	Quantity limited for 30 days
Clobetasone butyrate	
Clotrimazole	
Collagenase	
Dakin's solution	
Desonide	

Substances	Specifications
Desoximetasone	Quantity limited for 30 days
Deoxyribonuclease	
Dichloracetic acid	
Diclofenac, potassic and sodic	Pharmaceutical form intended for oral administration
	Quantity limited for 30 days
Diflucortolone valerate	Quantity limited for 30 days
Dyphenhydramine	Pharmaceutical forms intended for oral administration and administration per intramuscular, subcutaneous or intradermal injection
Econazole nitrate	
Epinephrine (adrenaline)	Pharmaceutical forms for the emergency treatment of anaphylactic reactions in the form of auto-injector or vial
	Pharmaceutical form associated with local anaesthetics
Erythromycin	
Ethyl chloride	
Fibrinolysin	
Flumetasone pivalate	
Fluocinolone acetonide	Quantity limited for 30 days
Fluocinode	Quantity limited for 30 days
5-fluorouracil	0.1% pharmaceutical form intended for topical application in the case of plantar warts resisting to first-line treatments
Formaline	
Framycetin sulfate	
Fusidic acid	
Gentamicin sulfate	
Gentian, violet	
Mineral and vegetal tar	
Gramicidin	
Halcinodide	Quantity limited for 30 days
Hexachlorophene	
Mineral oil	
Hydrocortisone and its salts	
Hydroxyzine hydrochloride	Pharmaceutical form intended for oral administration

Substances	Specifications
Ibuprofen	Pharmaceutical form intended for oral administration
	Quantity limited for 30 days
Povidone iodine	
Iodine tincture	
Isopropyl myristate	
Ketoconazole	
Lactic acid	
Lanolin	
Lidocaine and its salts	Pharmaceutical forms intended for topical application and administration by injection for local use only
Loratadine	Pharmaceutical form intended for oral administration
Mafenide and its salts	
Menthol	
Mepivacaine	Pharmaceutical form intended for administration by injection for local use only
Methylpolysiloxanes	
Methylprednisolone acetate	Pharmaceutical forms intended for topical application and administration by injection for local use only
Miconazole nitrate	
Mometasone furorate	
Mupirocin	
Naproxen	Pharmaceutical form intended for oral administration
	Quantity limited for 30 days
Neomycin sulfate	
Nystatin	
Oxiconazole	
Phenol	
Podophyllin	
Polymyxin B sulfate	
Pramoxine	
Prilocaine	Pharmaceutical forms intended for topical application and administration by injection for local use only

Substances	Specifications
Procaine	Pharmaceutical form intended for administration by injection for local use only
Resorcinol and its salts	
Rofecoxib	Pharmaceutical form intended for oral administration
	Quantity limited for 30 days
Diethylamine salicylate	
Magnesium salicylate	
Methyl salicylate	
Triethanolamine salicylate	
Salicylic acid	
Synthetic sebum	
Silicone	
Sodium thiosulfate	
Sulphur, colloidal, precipitate or sublimate	
Tazarotene	
Terbinafine	
Tetracaine and its salts	Pharmaceutical forms intended for topical application and administration by injection for local use only
Tioconazole	
Tolnaftate	
Triamcinolone acetonide	Quantity limited for 30 days
Triamcinolone hexacetonide	Pharmaceutical forms intended for administration by intramuscular or intradermal injection
	Quantity limited for 30 days
Trichloroacetic acid	
Urea	Pharmaceutical form intended for topical application, with a concentration of 30% or less
White petroleum jelly	
Zinc oxide".	

4. This Regulation comes into force on the fifteenth day following the date of its publication in the *Gazette officielle du Québec*.

5610

Gouvernement du Québec

O.C. 143-2003, 12 February 2003

An Act respecting the Québec sales tax
(R.S.Q., c. T-0.1)

Québec sales tax
— Amendments

CONCERNING the Regulation to amend the Regulation respecting the Québec sales tax

WHEREAS, under the first paragraph of section 677 of that Act respecting the Québec sales tax (R.S.Q., c. T-0.1), amended by section 174 of Chapter 9 of the Statutes of 2002 and by section 18 of Chapter 58 of the Statutes of 2002, the Government may make regulations to prescribe the measures required for the purposes of the Act;

WHEREAS the Regulation respecting the Québec sales tax was made by Order in Council 1607-92 dated 4 November 1992 under the Act respecting the Québec sales tax;

WHEREAS it is expedient to amend that regulation to give effect to the fiscal measures related amendments introduced into the Act respecting the Québec sales tax by Chapter 58 of the Statutes of 2002;

WHEREAS under section 12 of the Regulations Act (R.S.Q., c. R-18.1), a proposed regulation may be made without having been published as prescribed by section 8 of that Act if the authority making it is of the opinion that the fiscal nature of the norms established, amended or repealed in the regulation warrants it;

WHEREAS under section 18 of that Act, a regulation may come into force on the date of its publication in the *Gazette officielle du Québec* where the authority that has made it is of the opinion that the fiscal nature of the norms established, amended or repealed by the regulation warrants it;

WHEREAS the Government is of the opinion that the fiscal nature of the norms established, amended or revoked by the Regulation warrants the absence of prior publication and such coming into force;

WHEREAS under section 27 of that Act, the Act does not prevent a regulation from taking effect before the date of its publication in the *Gazette officielle du Québec* where the Act under which it is made expressly provides therefor;